LRE vs. MDC, CCT, ROAD, EME, PRIM, CCS, GEO, PHM, J, and MTH
Should you be buying Lancashire stock or one of its competitors? The main competitors of Lancashire include Mediclinic International (MDC), The Character Group (CCT), Roadside Real Estate (ROAD), Empyrean Energy (EME), Primorus Investments (PRIM), Crossword Cybersecurity (CCS), Georgian Mining (GEO), Phimedix Plc (PHM.L) (PHM), Jacobs Engineering Group (J), and Mithras Investment Trust (MTH). These companies are all part of the "construction" industry.
Lancashire vs.
Mediclinic International (LON:MDC) and Lancashire (LON:LRE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
Lancashire received 115 more outperform votes than Mediclinic International when rated by MarketBeat users. However, 57.33% of users gave Mediclinic International an outperform vote while only 44.53% of users gave Lancashire an outperform vote.
Mediclinic International pays an annual dividend of GBX 3 per share. Lancashire pays an annual dividend of GBX 18 per share and has a dividend yield of 3.1%. Mediclinic International pays out 1,304.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Lancashire pays out 34.3% of its earnings in the form of a dividend. Lancashire is clearly the better dividend stock, given its higher yield and lower payout ratio.
39.2% of Mediclinic International shares are owned by institutional investors. Comparatively, 60.5% of Lancashire shares are owned by institutional investors. 48.9% of Mediclinic International shares are owned by insiders. Comparatively, 0.6% of Lancashire shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Lancashire has a net margin of 37.12% compared to Mediclinic International's net margin of 4.99%. Lancashire's return on equity of 10.76% beat Mediclinic International's return on equity.
Lancashire has a consensus price target of GBX 781, indicating a potential upside of 35.59%. Given Lancashire's stronger consensus rating and higher probable upside, analysts clearly believe Lancashire is more favorable than Mediclinic International.
In the previous week, Lancashire had 1 more articles in the media than Mediclinic International. MarketBeat recorded 1 mentions for Lancashire and 0 mentions for Mediclinic International. Mediclinic International's average media sentiment score of 0.00 beat Lancashire's score of -0.99 indicating that Mediclinic International is being referred to more favorably in the media.
Mediclinic International has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Lancashire has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Lancashire has lower revenue, but higher earnings than Mediclinic International. Mediclinic International is trading at a lower price-to-earnings ratio than Lancashire, indicating that it is currently the more affordable of the two stocks.
Summary
Lancashire beats Mediclinic International on 14 of the 19 factors compared between the two stocks.
Get Lancashire News Delivered to You Automatically
Sign up to receive the latest news and ratings for LRE and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lancashire Competitors List
Related Companies and Tools
This page (LON:LRE) was last updated on 2/21/2025 by MarketBeat.com Staff
Free LRE Stock Alerts